Skip to content

A 8 weeks, randomized, double-blind human trial to evaluate the efficacy and safety of Fermented soybean(Cheonggukjang powder) on intestinal microflora and decrease of body fat

A 8 weeks, randomized, double-blind human trial to evaluate the efficacy and safety of Fermented soybean(Cheonggukjang powder) on intestinal microflora and decrease of body fat

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0007734
Enrollment
60
Registered
2022-09-23
Start date
2022-08-08
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : •TCC22-41(high content of effective microorganisms, Cheonggukjang powder): once a day, 1 pack once, after breakfast(3.3 g/day, Fermented soybean for 2.97 g/day) •TCC22-7(low conte

Sponsors

Wonkwang University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Males and females aged 19 or over and 70 or under at the screening examination 2) Participants whose BMI is 25kg/m^2 or over at the screening examination 3) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions

Exclusion criteria

Exclusion criteria: 1) Patients who have been taking products influencing body weight(absorption inhibitor and appetite inhibitor, body fat improvement health functional food or the medicine, beta blocker, diuretic, contraceptive, steroid, female hormone agent) within one month before the screening examination (refer to combination prohibition drug) 2) Patients who have undergone obesity surgery within one year 3) Patients who require Patients who have clinically significant acute or chronic cardio-cerebrovascular systems, endocrine systems, immune systems, respiratory systems, hepatic biliary systems, kidneys and urinary systems, neuropsychiatric systems, musculoskeletal systems, inflammatory and hematologic and tumorigenic, gastrointestinal diseases, etc. 4) Those with a history of significant hypersensitivity reactions to soybean and cheonggukjang ingredients 5) Patients who have received antipsychotic medication within three months before screening test 6) Patients who have or are suspected of alcoholism or substance abuse 7) Patients who have participated in other human trials within three months before screening test 8) Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

Design outcomes

Primary

MeasureTime frame
changes of intestinal microbiome;Inbody

Secondary

MeasureTime frame
anthropometric index;lipid metabolism index;body fat-related index;inflammatory index;blood glucose related index;monoenoic fatty acid

Countries

Korea, Republic of

Contacts

Public ContactA Lum Han

Wonkwang University Hospital

qibosarang@naver.com+82-63-859-2543

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026